Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02736266
Recruitment Status : Recruiting
First Posted : April 13, 2016
Last Update Posted : May 13, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 27, 2021
Estimated Study Completion Date : December 27, 2021
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):